Hebo Pharma's new-generation anti-CTLA-4 antibody HBM4003 was approved for two clinical trials in China

Hebo Pharmaceutical recently announced that the National Medical Products Administration (NMPA) of China approved its new generation of HBM4003 anti-CTLA-4 fully human monoclonal heavy chain antibody and PD-1 antibody for the treatment of advanced hepatocellular carcinoma (HCC) and other solid tumors Clinical trial application for patients, and clinical trial application for HBM4003 and PD-1 antibody combined treatment of advanced neuroendocrine tumor/carcinoma (NET/NEC) and other solid tumor patients
.

Prior to this, Hebo Medicine has obtained IND approval from the National Medical Products Administration (NMPA), the U.
S.
Food and Drug Administration (FDA) and the Australian Institutional Review Board (IRB) to carry out clinical trials, and to promote HBM4003 globally in an orderly manner.
Multiple clinical trials of monotherapy and combination therapy
.

Dr.
Wang Jinsong, Founder, Chairman and CEO of Hebo Medicine, said: "HBM4003 is a new generation of anti-CTLA-4 antibody.
Based on its unique mechanism of action, it has shown good safety and powerful anti-tumor effects in clinical studies.
Active
.
The approval of clinical trials for the two indications at the same time is another recognition of HBM4003, and it also makes us feel the responsibility and mission